ACS Medicinal Chemistry Letters
January 12, 2026
Anna C Renner, Robert B Kargbo
Two recent patent applications illustrate how psychedelic drug development is expanding beyond molecules and experiences toward deployable therapeutic systems. One focuses on solid-state optimization of a lysergamide analogue to ensure manufacturability and stability, while the other applies machine-learning-driven neurophysiological biomarkers to predict patient response. Together, they...
ACS Medicinal Chemistry Letters
January 12, 2026
Anna C Renner, Robert B Kargbo
Recent psychedelic patent activity highlights a strategic shift from experiential framing toward chemically and pharmacokinetically precise neurotherapeutics. Four recent patent applications collectively span solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor...
ACS Medicinal Chemistry Letters
November 10, 2025
Anna C Renner, Robert B Kargbo
High Resolution Image Download MS PowerPoint Slide Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT 2 A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure–activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that...
ACS Medicinal Chemistry Letters
October 9, 2025
Anna C Renner, Robert B Kargbo
Recent patents disclose complementary strategies to optimize psychedelic-assisted therapy. Novel psilocin prodrugs improve pharmacokinetics and stability, while digital systems enable cognitive state monitoring during treatment. Parallel advances in combining neuroplastogen drugs with transcranial electrical stimulation highlight a model-driven approach to enhance and personalize neural...
ACS Medicinal Chemistry Letters
March 11, 2025
Robert B Kargbo
Emerging innovations across psychedelics, artificial intelligence (AI), and communication technologies are reshaping healthcare and beyond. This Patent Highlight showcases advancement in sublingual delivery systems for psychedelics, asymmetric phenylethylamine compounds, AI-assisted communication positioning, and multi-modal data fusion, respectively. These inventions address challenges like...
ACS Medicinal Chemistry Letters
January 23, 2025
Robert B Kargbo
The intersection of artificial intelligence (AI), digital therapeutics, and advanced communication frameworks offers transformative opportunities for addressing mental health disorders, neurodegenerative diseases, and communication challenges in modern networks. This Patent Highlight examines three pivotal patents that introduce deuterated empathogens for safer psychiatric treatments,...
ACS Medicinal Chemistry Letters
September 7, 2022
Robert B Kargbo
Provided herein are MDMA and their analogs for the potential psychotherapy-assisted treatment of alcohol use disorder (AUD), post-traumatic stress disorder (PTSD), and a method of predicting dosing and patient response.
ACS Medicinal Chemistry Letters
August 22, 2022
Robert B Kargbo
ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTApplication of Deuterated N,N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological DisordersRobert B. Kargbo*Robert B. KargboUsona Institute, Fitchburg, Wisconsin 53711-5300, United States*E-mail: [email protected]More by Robert B. Kargbohttps://orcid.org/0000-0002-5539-6343Cite this: ACS Med. Chem. Lett. 2022, 13, 9,...
ACS Medicinal Chemistry Letters
November 8, 2021
Robert B Kargbo
ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTThe Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic SettingRobert B. Kargbo*Robert B. KargboUsona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States*Email: [email protected]More by Robert B. Kargbohttps://orcid.org/0000-0002-5539-6343Cite this: ACS Med. Chem. Lett. 2021, 12, 12,...